@vasilios .... this thought had crossed my mind given that some on here claim SI is apparently a nightmare to deal with - I obviously cannot confirm or deny this ?
I am not sure a top 10 global pharma like Novartis will want to report to Mesoblast on an ongoing basis so it makes sense for them to take us out ..... it would need to be through a Scheme of Arrangement though to get around the SI / Thorney blocking stake.
Novartis have definitely had the red carpet rolled out for them in the last 12 months so they have looked under the hood (in more than one indication I am sure) and if they believe the synergies with Rexlemestrocel-L and Entresto are worth pursuing as well as Remestemcel_L for all cause ARDS, then I think they will want full autonomy moving forward on all indications ?
Time will tell I guess ... GLTAH
New Covid 19 treatment, page-173
-
- There are more pages in this discussion • 272 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add MSB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.03 |
Change
0.080(8.42%) |
Mkt cap ! $1.176B | |||
| Open | High | Low | Value | Volume |
| 95.5¢ | $1.03 | 95.0¢ | $43.38M | 42.28M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 4 | 72752 | $1.01 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.03 | 205100 | 2 |
View Market Depth
| Last trade - 16.10pm 30/08/2024 (20 minute delay) ? |
| MSB (ASX) Chart |